Scpharmaceuticals ( (SCPH) ) has released its Q4 earnings. Here is a breakdown of the information Scpharmaceuticals presented to its investors.
scPharmaceuticals Inc., a pharmaceutical company focused on innovative cardiorenal healthcare solutions, has released its financial results for the fourth quarter and full year of 2024, highlighting significant growth and strategic advancements.
The company reported a notable increase in revenue, with fourth-quarter earnings reaching $12.2 million and full-year revenue totaling $36.3 million, marking a 167% increase from the previous year. This growth is attributed to the rising demand for FUROSCIX, their primary product, and the expansion of its label to include treatment for edema in chronic kidney disease patients, recently approved by the FDA.
Key financial metrics reveal that scPharmaceuticals filled approximately 41,000 FUROSCIX doses in 2024, with a 23% increase in the fourth quarter alone. The company also expanded its network of prescribers and integrated delivery networks significantly. Despite these advancements, the company reported a net loss of $85.1 million for the year, driven by increased operational costs and strategic investments in R&D and SG&A.
Looking forward, scPharmaceuticals is poised for further growth with plans to launch the expanded FUROSCIX indication in April 2025 and the anticipated submission of a new autoinjector application. The company remains optimistic about its strategic initiatives, including an expanded sales force and the impact of Medicare Part D redesign, which are expected to drive future revenue growth.